<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[RSS Feed]]></title><description><![CDATA[RSS Feed]]></description><link>http://direct.ecency.com</link><image><url>http://direct.ecency.com/logo512.png</url><title>RSS Feed</title><link>http://direct.ecency.com</link></image><generator>RSS for Node</generator><lastBuildDate>Tue, 21 Apr 2026 09:59:16 GMT</lastBuildDate><atom:link href="http://direct.ecency.com/created/biosimilar/rss.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Biosimilar drugs promise to slash health-care costs in rich countries - Pill bills]]></title><description><![CDATA[“IT’S THE prices, stupid.” That simple assessment of America’s wildly expensive health-care system was made 15 years ago by Uwe Reinhardt, a health economist who died last year. Health costs as a proportion]]></description><link>http://direct.ecency.com/dlike/@unicomcenbd/biosimilar-drugs-promise-to-slash-health-care-costs-in-rich-countries--pill-bills</link><guid isPermaLink="true">http://direct.ecency.com/dlike/@unicomcenbd/biosimilar-drugs-promise-to-slash-health-care-costs-in-rich-countries--pill-bills</guid><category><![CDATA[dlike]]></category><dc:creator><![CDATA[unicomcenbd]]></dc:creator><pubDate>Fri, 16 Nov 2018 09:41:57 GMT</pubDate><enclosure url="https://images.ecency.com/p/3HaJVw3AYyXB7zVK4xufUCYSEyHDF1GbmXttP95tNu88aD8Be3Nt6stzqXjMVj8eTwkHJH5xoT254EvxDy3E34zX9NoJUFWV6f58Zen?format=match&amp;mode=fit" length="0" type="false"/></item><item><title><![CDATA[Biosimilars need huge investments, longer timelines]]></title><description><![CDATA[( What are Biosimilars? A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are officially approved]]></description><link>http://direct.ecency.com/currentaffairs/@a3rishk/biosimilars-need-huge-investments-longer-timelines</link><guid isPermaLink="true">http://direct.ecency.com/currentaffairs/@a3rishk/biosimilars-need-huge-investments-longer-timelines</guid><category><![CDATA[currentaffairs]]></category><dc:creator><![CDATA[a3rishk]]></dc:creator><pubDate>Fri, 07 Sep 2018 14:11:00 GMT</pubDate><enclosure url="https://images.ecency.com/p/RGgukq5E6HBM2jscGd4Sszpv94XxHH2uqxMY9z21vaqHt4ffCaXvtgoEZjvreV8ufA2s4VYjW16hcfWopnfLps3QR3WdCk6fkYUB67pmsYkC29VYvH2XYa911BNRsEW?format=match&amp;mode=fit" length="0" type="false"/></item><item><title><![CDATA[한국 부자 순위 2위 [ 셀트리온 서정진 회장, 재산: 12조원 ]]]></title><description><![CDATA[최근 한국 부자 순위를 뒤흔든 사나이가 있습니다. 셀트리온 서정진 회장인데요, 포브스가 발표한 한국 50대 부자순위에서 서정진 회장은 이재용 삼성그룹 부회장, 서경배 아모레퍼시픽 회장 등을 제치고 2위를 차지하였습니다. Forbes에 따르면 서정진 회장의 재산 규모는 $11B (약 12조3035억원)으로 1위인 이건희 회장의 재산 ($20.6B, 약 23조]]></description><link>http://direct.ecency.com/kr/@jyinvest/2-12</link><guid isPermaLink="true">http://direct.ecency.com/kr/@jyinvest/2-12</guid><category><![CDATA[kr]]></category><dc:creator><![CDATA[jyinvest]]></dc:creator><pubDate>Sun, 29 Jul 2018 03:11:33 GMT</pubDate><enclosure url="https://images.ecency.com/p/BM7WWisF8H7LG2isfZRNnDvVkCUXFjtG8aDLsTevZf2Y81bfxe1zvnPG3EcfpU1KD4DSghcBPcaSwbR3Ub6NnUJAGXjaQkQhdH8Um664QLtnqnX6g4m2cTbk44BAe9npwLi2xzjou4iG2m5sfBreSQs3Xdu1JpYaFZ6uD92ue524DVHkyCSX95cNTWuwpKaoPUttokwrWUfjYca6FxShKbgfktcWTRMkYUFESuL?format=match&amp;mode=fit" length="0" type="false"/></item><item><title><![CDATA[셀트리온 주가 전망 [ 램시마, 트룩시마, 허쥬마 바이오시밀러 실적 ]]]></title><description><![CDATA[시가총액 기준 셀트리온은 국내 최대 규모의 바이오시밀러 전문 기업으로 셀트리온제약, 셀트리온 화학연구소, 셀트리온 돈, 셀트리온예브라지아, 셀트리온유럽, Celltrion Pharma USA를 연결대상 종속회사로 두고 있습니다. 참고: 연결실적은 셀트리온뿐만아니라 연결대상 종속회사들의 실적을 모두 합산한 수치입니다. 사업부문별 셀트리온 매출 구성 비중 ('18,]]></description><link>http://direct.ecency.com/kr/@jyinvest/3rzntr</link><guid isPermaLink="true">http://direct.ecency.com/kr/@jyinvest/3rzntr</guid><category><![CDATA[kr]]></category><dc:creator><![CDATA[jyinvest]]></dc:creator><pubDate>Fri, 13 Jul 2018 06:44:27 GMT</pubDate><enclosure url="https://images.ecency.com/p/EEEoA8oLaAxsTkPYAARp78o5cJA1o6Chv9x98TzCFT6v5GJYvmmkTFsWJG7Wt7DSxRYF84wjA9tbmuWPVpxWVf4fBbAvdAX3C82Z6GLD59YEkeBPB9BhC9bWmQzUyAmDhCBMM8X6vdhtyKERBc71x?format=match&amp;mode=fit" length="0" type="false"/></item><item><title><![CDATA[Global Biosimilar Drug Market: Growth to be driven by Steady Influx of Investment in Healthcare Sector]]></title><description><![CDATA[A biosimilar is a biological medicine, approved by the regulatory bodies based on a high similarity to a pre-existing approved innovative biological product, also referred as reference medicine or originator]]></description><link>http://direct.ecency.com/biosimilar/@sunilmarket/global-biosimilar-drug-market-growth-to-be-driven-by-steady-influx-of-investment-in-healthcare-sector</link><guid isPermaLink="true">http://direct.ecency.com/biosimilar/@sunilmarket/global-biosimilar-drug-market-growth-to-be-driven-by-steady-influx-of-investment-in-healthcare-sector</guid><category><![CDATA[biosimilar]]></category><dc:creator><![CDATA[sunilmarket]]></dc:creator><pubDate>Tue, 22 May 2018 13:11:18 GMT</pubDate></item><item><title><![CDATA[Assisted Reproductive Technology Market - Conceiving With Hi-Tech Fertility Treatments]]></title><description><![CDATA[The global Assisted Reproductive Technology (ART) market size was valued at USD 21.9 billion in 2016 and is expected to reach USD 36.7 billion in 2025, growing at a CAGR of over 6% over the forecast period.]]></description><link>http://direct.ecency.com/biosimilar/@sunilmarket/6ukp24-assisted-reproductive-technology-market-conceiving-with-hi-tech-fertility-treatments</link><guid isPermaLink="true">http://direct.ecency.com/biosimilar/@sunilmarket/6ukp24-assisted-reproductive-technology-market-conceiving-with-hi-tech-fertility-treatments</guid><category><![CDATA[biosimilar]]></category><dc:creator><![CDATA[sunilmarket]]></dc:creator><pubDate>Tue, 22 May 2018 13:05:33 GMT</pubDate></item><item><title><![CDATA[Biosimilar Market is Increasing Rapidly Growing to Rapid Growth in Automotive Industry –Xpodence Research]]></title><description><![CDATA[Market Overview A biosimilar is a biological medicine, approved by the regulatory bodies based on a high similarity to a pre-existing approved innovative biological product, also referred as reference]]></description><link>http://direct.ecency.com/biosimilar/@xpodenceresearch/biosimilar-market-is-increasing-rapidly-growing-to-rapid-growth-in-automotive-industry-xpodence-research</link><guid isPermaLink="true">http://direct.ecency.com/biosimilar/@xpodenceresearch/biosimilar-market-is-increasing-rapidly-growing-to-rapid-growth-in-automotive-industry-xpodence-research</guid><category><![CDATA[biosimilar]]></category><dc:creator><![CDATA[xpodenceresearch]]></dc:creator><pubDate>Mon, 14 May 2018 15:52:33 GMT</pubDate></item><item><title><![CDATA[Current Trends and Future Growth of Remicade Biosimilar Market]]></title><description><![CDATA[Qyresearchreports include new market research report Global Remicade Biosimilar Market Professional Survey Report 2018 to its huge collection of research reports. This report studies Remicade Biosimilar]]></description><link>http://direct.ecency.com/remicade/@research-reports/current-trends-and-future-growth-of-remicade-biosimilar-market</link><guid isPermaLink="true">http://direct.ecency.com/remicade/@research-reports/current-trends-and-future-growth-of-remicade-biosimilar-market</guid><category><![CDATA[remicade]]></category><dc:creator><![CDATA[research-reports]]></dc:creator><pubDate>Tue, 27 Mar 2018 11:27:39 GMT</pubDate></item><item><title><![CDATA[Global Adalimumab Biosimilar Sales Market Share, Trends, Analysis, Top-players & Future Forecast by 2025]]></title><description><![CDATA[An up-to-date research report has been disclosed by Market Research Hub highlighting the title “Global Adalimumab Biosimilar Sales Market Report 2018” which provides an outlook of current market growth]]></description><link>http://direct.ecency.com/pharmaceutical/@sumaanraina/global-adalimumab-biosimilar-sales-market-share-trends-analysis-top-players-and-future-forecast-by-2025</link><guid isPermaLink="true">http://direct.ecency.com/pharmaceutical/@sumaanraina/global-adalimumab-biosimilar-sales-market-share-trends-analysis-top-players-and-future-forecast-by-2025</guid><category><![CDATA[pharmaceutical]]></category><dc:creator><![CDATA[sumaanraina]]></dc:creator><pubDate>Tue, 06 Mar 2018 12:33:30 GMT</pubDate></item><item><title><![CDATA[Adalimumab Biosimilar Market 2018 Industry Size, Share, Growth and Global Forecast to 2025]]></title><description><![CDATA[Adalimumab Biosimilar Industry 2018 market Research Report gives the analysis of the international market including development history, competitive landscape analysis, and major regions' development status]]></description><link>http://direct.ecency.com/adalimumab/@orianresearch/adalimumab-biosimilar-market-2018-industry-size-share-growth-and-global-forecast-to-2025</link><guid isPermaLink="true">http://direct.ecency.com/adalimumab/@orianresearch/adalimumab-biosimilar-market-2018-industry-size-share-growth-and-global-forecast-to-2025</guid><category><![CDATA[adalimumab]]></category><dc:creator><![CDATA[orianresearch]]></dc:creator><pubDate>Thu, 01 Mar 2018 09:18:15 GMT</pubDate></item><item><title><![CDATA[Global Biosimilar Monoclonal Antibodies Market 2018 Size, Share, Demand and Analysis 2023]]></title><description><![CDATA[The Biosimilar Monoclonal Antibodies Market 2018 inspects the execution of the Biosimilar Monoclonal Antibodies advertise, encasing a top to bottom judgment of the Biosimilar Monoclonal Antibodies showcase]]></description><link>http://direct.ecency.com/pharmaceuticals/@marketsshares/global-biosimilar-monoclonal-antibodies-market-2018-size-share-demand-and-analysis-2023</link><guid isPermaLink="true">http://direct.ecency.com/pharmaceuticals/@marketsshares/global-biosimilar-monoclonal-antibodies-market-2018-size-share-demand-and-analysis-2023</guid><category><![CDATA[pharmaceuticals]]></category><dc:creator><![CDATA[marketsshares]]></dc:creator><pubDate>Wed, 21 Feb 2018 08:39:15 GMT</pubDate><enclosure url="https://images.ecency.com/p/21PRtjKRXPQyotRPt1Hd7fPufGf1WCpCvB7qBKbTk9naVwA37KDUcFJTJzWFm1CawfWMpXN5ZgRxR38knnQnw4if5Tqe4DnE5D7k9BPCuu9k84ZTDnpZuQDfmZ8YXGZ9Mr8rLA1E94hQiG5gmyFZgVt?format=match&amp;mode=fit" length="0" type="false"/></item><item><title><![CDATA[Bio-similar Market Trends and Industry Overview 2017 - 2025 Available on Reports Monitor]]></title><description><![CDATA[The " Global Biosimilar market, By Recombinant Products (Non-Glycosylated Proteins, Glycosylated Proteins, peptides and others) By Application (Oncology, Blood Disorders, Chronic and Auto-immune Disease,]]></description><link>http://direct.ecency.com/biosimilar/@danielmartinez/bio-similar-market-trends-and-industry-overview-2017-2025-available-on-reports-monitor</link><guid isPermaLink="true">http://direct.ecency.com/biosimilar/@danielmartinez/bio-similar-market-trends-and-industry-overview-2017-2025-available-on-reports-monitor</guid><category><![CDATA[biosimilar]]></category><dc:creator><![CDATA[danielmartinez]]></dc:creator><pubDate>Thu, 11 Jan 2018 06:51:45 GMT</pubDate></item><item><title><![CDATA[바이오시밀러 파이프라인 2017]]></title><description><![CDATA[바이오시밀러에 대해 간단히 설명드리자면 의약품의 구분에서 부터 시작해야겠네요. 의약품에는 크게 합성의약품과 바이오의약품으로 나눠집니다. 합성의약품은 '아스피린'과 같이 화학적으로 합성한 의약품으로서 전통적으로 많이 쓰여 왔고, 작은 분자량으로 구성되어 있고, 가격이 저렴한 장점이 있습니다. 바이오의약품은 Recombinant DNA (유전자재조합) 기술, Cell]]></description><link>http://direct.ecency.com/kr/@terrykim2479/2017</link><guid isPermaLink="true">http://direct.ecency.com/kr/@terrykim2479/2017</guid><category><![CDATA[kr]]></category><dc:creator><![CDATA[terrykim2479]]></dc:creator><pubDate>Tue, 25 Jul 2017 03:03:51 GMT</pubDate><enclosure url="https://images.ecency.com/p/AmRc67RgYaWVEa5TxnoPRiGMS1Ae6MyfiK8oyuudvtaMcXyTiB8w3KX5gzyjVaJh5yddXJL2WSAxy3ZX7BorsaiaZgtw5veKKEJ5pa2PiHp6cWpMEjbMJ4vZTQ3UTzJWZxZrsyic98t72Mnx5GQBvAFLDwgjyEBG?format=match&amp;mode=fit" length="0" type="false"/></item></channel></rss>